HCM
Hutchison China MediTech

488
Mkt Cap
$2.53B
Volume
75,889.00
52W High
$19.50
52W Low
$11.51
PE Ratio
5.42
HCM Fundamentals
Price
$14.18
Prev Close
$14.53
Open
$14.62
50D MA
$15.64
Beta
1.01
Avg. Volume
42,820.09
EPS (Annual)
$0.2163
P/B
2.06
Rev/Employee
$348,159.63
Loading...
Loading...
News
all
press releases
HUTCHMED (NASDAQ:HCM) Rating Increased to Buy at Wall Street Zen
Wall Street Zen raised HUTCHMED from a "hold" rating to a "buy" rating in a research report on Sunday...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
HUTCHMED (NASDAQ:HCM) Lowered to Hold Rating by Wall Street Zen
Wall Street Zen downgraded shares of HUTCHMED from a "buy" rating to a "hold" rating in a research report on Saturday...
MarketBeat·13d ago
News Placeholder
Best Momentum Stock to Buy for August 19th
CENX, MC and HCM made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 19, 2025.
Zacks·3mo ago
News Placeholder
How Much Upside is Left in HUTCHMED (HCM)? Wall Street Analysts Think 73.52%
Zacks·5mo ago
News Placeholder
Wall Street Analysts See a 68.3% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
Zacks·6mo ago
News Placeholder
Hutchmed Stock Hits Over One-Month High After China Accepts Kidney Cancer NDA Filed With Partner Innovent Biologics
China's drug regulator accepted the companies’ NDA for a combination therapy targeting advanced renal cell carcinoma.
Stocktwits·6mo ago
News Placeholder
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT (Sintilimab Injection) in Combination with ELUNATE (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT (Sintilimab Injection) in Combination with ELUNATE (Fruquintinib) for the Treatment of Advanced Endometrial Cancer Innovent...
PR Newswire·1y ago
News Placeholder
FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket PR Newswire VANCOUVER, BC, Oct. 4, 2024 USA News Group...
PR Newswire·1y ago
News Placeholder
HUTCHMED Updates Share Capital and Voting Rights
HUTCHMED (China) Limited (HK:0013) has released an update. HUTCHMED (China) Limited has announced its total number of voting rights, revealing an i...
TipRanks Financial Blog·1y ago
News Placeholder
HUTCHMED to Unveil New Cancer Drug Data at AACR 2024
Hutchmed (China) Limited (HCM) has released an update. HUTCHMED (China) Limited is set to present new and updated data on its cancer treatment comp...
TipRanks Financial Blog·2y ago

Latest HCM News

View

Advertisement|Remove ads.

Advertisement|Remove ads.